AMAG Pharmaceuticals, Inc. to Participate in the Leerink Global Healthcare Conference

AMAG Pharmaceuticals logo

WALTHAM, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will participate in an analyst-led fireside chat at the Leerink Global Healthcare Conference in New York, NY. The fireside chat will take place on Wednesday, February 12, 2014 at 8:00 a.m. ET and will include a discussion on the company's business, regulatory status, strategy and growth prospects.

A live audio webcast of the discussion will be accessible through the Investors section of the company's website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for 30 days.

About AMAG

AMAG Pharmaceuticals, Inc. is a rapidly growing, specialty pharmaceutical company, supported by a talented and passionate workforce. AMAG currently markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in the United States. Along with driving organic growth of its products, AMAG intends to expand its portfolio with additional commercial-stage specialty products. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers. The company's primary goal is to bring to market therapies that provide clear benefits and improve patients' lives. For additional company information, please visit www.amagpharma.com.

CONTACT: AMAG Pharmaceuticals, Inc. Contact: Amy Sullivan, 617-498-3303

Source:AMAG Pharmaceuticals, Inc.